HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL

被引:109
作者
Pathil, A
Armeanu, S
Venturelli, S
Mascagni, P
Weiss, TS
Gregor, M
Lauer, UM
Bitzer, M
机构
[1] Med Univ Clin, Dept Internal Med 1, D-72076 Tubingen, Germany
[2] Italfarmaco Res Ctr, Milan, Italy
[3] Univ Hosp, Ctr Liver Cell Res, Regensburg, Germany
关键词
D O I
10.1002/hep.21054
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) displays a striking resistance to chemotherapeutic drugs or innovative tumor cell apoptosis-inducing agents such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Recently, we found 2 histone deacetylase inhibitors (HDAC-I), valproic acid and ITF2357, exhibiting inherent therapeutic activity against HCC. In TRAIL-sensitive cancer cells, the mechanism of HDAC-I-induced cell death has been identified to be TRAIL-dependent by inducing apoptosis in an autocrine fashion. In contrast, in HCC-derived cells' a prototype of TRAIL-resistant tumor cells, we found a HDAC-I-mediated apoptosis that works independently of TRAIL and upregulation of death receptors or their cognate ligands. Interestingly, TRAIL resistance could be overcome by a combinatorial application of HDAC-I and TRAIL, increasing the fraction of apoptotic cells two- to threefold compared with HDAC-I treatment alone, whereas any premature HDAC-I withdrawal rapidly restored TRAIL resistance. Furthermore, a tumor cell-specific down-regulation of the FLICE inhibitory protein (FLIP) was observed, constituting a new mechanism of TRAIL sensitivity restoration by HDAC-I. In contrast, FLIP levels in primary human hepatocytes (PHH) from different donors were upregulated by HDAC-I. Importantly, combination HDAC-I/TRAIL treatment did not induce any cytotoxicity in nonmalignant PHH. In conclusion, HDAC-I compounds, exhibiting a favorable in vivo profile and inherent activity against HCC cells, are able to selectively overcome the resistance of HCC cells toward TRAIL. Specific upregulation of intracellular FLIP protein levels in nonmalignant hepatocytes could enhance the therapeutic window for clinical applications of TRAIL, opening up a highly specific new treatment option for advanced HCC.
引用
收藏
页码:425 / 434
页数:10
相关论文
共 42 条
[1]   Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate [J].
Armeanu, S ;
Bitzer, M ;
Lauer, UM ;
Venturelli, S ;
Pathil, A ;
Krusch, M ;
Kaiser, S ;
Jobst, K ;
Smirnow, I ;
Wagner, A ;
Steinle, A ;
Salih, HR .
CANCER RESEARCH, 2005, 65 (14) :6321-6329
[2]   Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357 [J].
Armeanu, S ;
Pathil, A ;
Venturelli, S ;
Mascagni, P ;
Weiss, TS ;
Göttlicher, M ;
Gregor, M ;
Lauer, UM ;
Bitzer, M .
JOURNAL OF HEPATOLOGY, 2005, 42 (02) :210-217
[3]  
Armeanu S, 2003, CANCER RES, V63, P2369
[4]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[5]   The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis [J].
Bin, LH ;
Li, XY ;
Xu, LG ;
Shu, HB .
FEBS LETTERS, 2002, 510 (1-2) :37-40
[6]   Sendai virus infection induces apoptosis through activation of caspase-8 (FLICE) and caspase-3 (CPP32) [J].
Bitzer, M ;
Prinz, F ;
Bauer, M ;
Spiegel, M ;
Neubert, WJ ;
Gregor, M ;
Schulze-Osthoff, K ;
Lauer, U .
JOURNAL OF VIROLOGY, 1999, 73 (01) :702-708
[7]  
Burns TF, 2001, J BIOL CHEM, V276, P37879
[8]   Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum [J].
Burroughs, A ;
Hochhauser, D ;
Meyer, T .
LANCET ONCOLOGY, 2004, 5 (07) :409-418
[9]   High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma [J].
Chan, KL ;
Guan, XY ;
OI-Lin, I .
HUMAN PATHOLOGY, 2004, 35 (11) :1324-1331
[10]  
Chen XP, 2003, WORLD J GASTROENTERO, V9, P2433